Our findings demonstrated the beneficial effect of NOP2 inhibitors on tumor growth in patients with HCC and indicated the possibility of using them in combination with sorafenib, thereby facilitating the development of anti-HCC drugs and therapeutic strategies in the future. The gene discussed is NOP2; the disease is hepatocellular carcinoma.